Endo Q3 top line down 2%; ytd cash flow down 40%

Endo International (NASDAQ:ENDP) Q3 results:

Revenues: $729.4M (-2.2%); Branded Pharma: $217M (-1.4%); Specialty Products: $132M (+17.9%); Sterile Injectables: $264M (+11.4%).

Net loss: ($41.4M) (+71.7%); non-GAAP net income: $138.1M (-16.2%); loss/share: ($0.18) (+72.3%); non-GAAP EPS: $0.60 (+15.5%); non-GAAP EBITDA: $321.1M (-2.2%).

Cash flow ops (9 mo.): $119.2M (-39.5%).

2019 guidance: Revenues: $2.86B – 2.89B from $2.76B – 2.96B; non-GAAP EPS: $2.10 – 2.25 from $2.00 – 2.25; non-GAAP EBITDA: $1.26B – 1.30B from $1.24B – 1.34B.

https://seekingalpha.com/news/3514081-endo-q3-top-line-2-percent-ytd-cash-flow-40-percent-shares-3-percent-hours